Business Context and Reporting Period
This Form 8-K Current Report was filed by Apogee Therapeutics, Inc. (APGE) on March 23, 2026. The filing discloses positive maintenance data from Part A of the Phase 2 APEX clinical trial for zumilokibart (APG777), an anti-IL-13 antibody candidate for moderate-to-severe atopic dermatitis (AD). The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and operational milestones.
Material Changes and Clinical Results
The primary material event is the announcement of 52-week maintenance data for zumilokibart (360mg) in the APEX Phase 2 Part A trial. Key efficacy results include:
- EASI 75 Maintenance: 75% (3-month dosing) and 85% (6-month dosing) among Week 16 responders; 88% and 81% overall response among all patients, respectively.
- vIGA 0/1 Maintenance: 86% (3-month dosing) and 78% (6-month dosing) among Week 16 responders; 72% and 52% overall response among all patients, respectively.
- Itch Reduction: 77% reduction (3-month dosing) and 67% reduction (6-month dosing) among Week 16 responders; 73% and 64% overall response among all patients, respectively.
- Deep Remission: EASI 90 overall response was 75% (3-month) and 48% (6-month); EASI 100 overall response was 41% (3-month) and 19% (6-month).
Safety data indicated the drug was well tolerated with a safety profile consistent with the class. Treatment-emergent adverse events (TEAEs) occurred in 71.4% of patients, with serious TEAEs at 0.8% and a discontinuation rate due to TEAEs of 3.4%. Common TEAEs included noninfective conjunctivitis (13.4%) and upper respiratory tract infection (12.6%).
Guidance, Outlook, and Risks
Management outlined the following anticipated milestones for 2026:
- Q2 2026: Readout of Phase 2 APEX Part B (16-week) induction data.
- 2H 2026: Initiation of Phase 3 trials for zumilokibart in AD, subject to clinical and regulatory outcomes.
- 2H 2026: 24-week readout for the Phase 1b head-to-head trial of APG279 (APG777+APG990) vs. DUPIXENT.
- 2H 2026: Announcement of further clinical trial plans for zumilokibart in asthma and eosinophilic esophagitis.
The Company projects a potential commercial launch in 2029, targeting a $50 billion AD market. Risks include the dependency of Phase 3 initiation on the success of Part B induction data and regulatory outcomes.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and data presentation (Exhibit 99.2) for detailed statistical analysis.
- Monitor the Q2 2026 readout of the APEX Part B dose optimization trial to confirm the selected dose for Phase 3.
- Assess the Company's cash runway given the anticipated initiation of Phase 3 trials in late 2026.
- Review the safety profile details regarding noninfective conjunctivitis and upper respiratory tract infections in the full dataset.
- Confirm the timeline for the APG279 head-to-head trial readout against DUPIXENT in the second half of 2026.